9,198 results on '"Cefepime"'
Search Results
2. Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing (DACAT)
- Author
-
National Institute of Allergy and Infectious Diseases (NIAID) and Kimberly Blumenthal, MD, MSc, Principal Investigator
- Published
- 2024
3. Cefepime-taniborbactam vs Meropenem in Adults With VABP or Ventilated HABP (CERTAIN-2)
- Author
-
Biomedical Advanced Research and Development Authority
- Published
- 2024
4. Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) (POPS or POP02)
- Author
-
The Emmes Company, LLC and Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- Published
- 2024
5. Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia (ELSA-FN)
- Published
- 2024
6. PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN
- Author
-
Merck Sharp & Dohme LLC
- Published
- 2024
7. Choosing the Best Antibiotic to Protect Friendly Gut Bacteria During the Course of Stem Cell Transplant
- Published
- 2024
8. A Study to Investigate PK, Safety, Tolerability of Cefepime-enmetazobactam in Pediatric Participants With cUTI
- Author
-
Linical Co., Ltd.
- Published
- 2024
9. Waveform Window #57: Cefepime Neurotoxicity in EEG.
- Author
-
Shugan, Adam
- Subjects
- *
SYNDROMES , *MYOCLONUS , *NEUROTOXICOLOGY , *ELECTROENCEPHALOGRAPHY , *DRUG therapy , *NEUROSYPHILIS , *OSTEOMYELITIS , *CEFEPIME , *GANGRENE , *TOES , *SYMPTOMS - Abstract
The article describes cases abnormalities seen on electroencephalography (EEG) from patients experiencing neurotoxicity induced by cefepime, a cephalosporin antibiotic. A 65-year old male with a history of chronic hepatitis C and chronic right middle cerebral artery infarcts from a gliosis demonstrated right frontal sharps. A 64-year old male demonstrated myoclonic status epilepticus. An 87-year old male showed generalized sharp discharges considered as an ictal-interical continuum pattern.
- Published
- 2024
- Full Text
- View/download PDF
10. Three novel Enterobacter cloacae bacteriophages for therapeutic use from Ghanaian natural waters.
- Author
-
Lyytinen, O. L., Dapuliga, C., Wallinger, D., Patpatia, S., Audu, B. J., and Kiljunen, S. J.
- Subjects
- *
ENTEROBACTER cloacae , *BACTERIOPHAGES , *DRUG resistance in bacteria , *GHANAIANS , *MEROPENEM , *ENTEROBACTER , *CEFEPIME - Abstract
Infections caused by multidrug-resistant (MDR) bacteria are a growing global concern. Enterobacter cloacae complex (ECC) species are particularly adept at developing antibiotic resistance. Phage therapy is proposed as an alternative treatment for pathogens that no longer respond to antibiotics. Unfortunately, ECC phages are understudied when compared to phages of many other bacterial species. In this Ghanaian-Finnish study, we isolated two ECC strains from ready-to-eat food samples and three novel phages from natural waters against these strains. We sequenced the genomic DNA of the novel Enterobacter phages, fGh-Ecl01, fGh-Ecl02, and fGh-Ecl04, and assessed their therapeutic potential. All of the phages were found to be lytic, easy to propagate, and lacking any toxic, integrase, or antibiotic resistance genes and were thus considered suitable for therapy purposes. They all were found to be related to T4-type viruses: fGh-Ecl01 and fGh-Ecl04 to karamviruses and fGh-Ecl02 to agtreviruses. Testing of Finnish clinical ECC strains showed promising susceptibility to these novel phages. As many as 61.1% of the strains were susceptible to fGh-Ecl01 and fGh-Ecl04, and 7.4% were susceptible to fGh-Ecl02. Finally, we investigated the susceptibility of the newly isolated ECC strains to three antibiotics – meropenem, ciprofloxacin, and cefepime – in combination with the novel phages. The use of phages and antibiotics together had synergistic effects. When using an antibiotic-phage combination, even low concentrations of antibiotics fully inhibited the growth of bacteria. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Activity of propyl‐propane‐thiosulfinate and propyl‐propane‐thiosulfonate against carbapenem‐resistant Gram‐negative bacteria.
- Author
-
Sorlózano‐Puerto, Antonio, Cerezo‐Collado, Laura, Roca‐Lagrilliere, Elvira, Baños‐Arjona, Alberto, and Gutiérrez‐Fernández, José
- Subjects
- *
CARBAPENEM-resistant bacteria , *GRAM-negative bacteria , *CEFTAZIDIME , *BACTERICIDAL action , *PIPERACILLIN , *CEFOTAXIME , *CEFEPIME - Abstract
Organosulfur compounds derived from plants of the Allium genus, such as propyl‐propane‐thiosulfinate (PTS) and propyl‐propane‐thiosulfonate (PTSO), have been proposed as an alternative in antibiotic resistance. The aim of this study was to compare the activity of these substances with other antibiotics against clinical isolates of carbapenem‐resistant (CAR‐R) and carbapenem‐susceptible (CAR‐S) Gram‐negative bacteria. A total of 126 clinical isolates of CAR‐R and 155 CAR‐S bacteria were selected, including Enterobacterales, A. baumannii and P. aeruginosa. The antibiotic susceptibility of all isolates was assessed using the microdilution and Kirby–Bauer methods for PTS, PTSO, amoxicillin/clavulanate, piperacillin/tazobactam, cefotaxime, ceftazidime, cefepime, imipenem, ciprofloxacin, and amikacin. Both PTS and PTSO demonstrated in vitro bactericidal activity against CAR‐R Enterobacteriaceae and A. baumannii, with no significant difference in activity compared to their response against CAR‐S isolates. However, both compounds were less active against P. aeruginosa than against any of the other bacteria, regardless of their resistance to carbapenems. In all cases, the minimum inhibitory concentration values of PTSO were significantly lower than those of PTS. These findings offer valuable information about the potential antibacterial use of these substances, particularly against infections that currently have limited therapeutic options. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Case Report: Cefepime Induced Neurotoxicity Following a Change in Infusion Time.
- Author
-
Stratton, Kendall and Davis, Kelly W.
- Subjects
- *
KIDNEY physiology , *SYNDROMES , *PNEUMONIA , *KIDNEY function tests , *ANTIBIOTICS , *NEUROTOXICOLOGY , *BRAIN diseases , *CEFEPIME , *DISCHARGE planning , *INTRAVENOUS therapy , *DRUG monitoring , *ANTI-infective agents , *PARENTERAL infusions - Abstract
Purpose: Cefepime is an antibiotic associated with cefepime induced neurotoxicity (CIN), particularly in those with reduced renal function, or in cases of inappropriate medication dosing. This report describes a case of CIN associated with a change in infusion duration from 180 to30 minutes, which to the best of our knowledge has not been previously reported in the literature. Summary: A 73-year old male was treated with extended infusion cefepime over 180 minutes while hospitalized with recurrent pneumonia. On discharge, cefepime was continued as outpatient parenteral antimicrobial therapy (OPAT) administered over 30 minutes. The patient began to experience symptoms of neurotoxicity after 1 day of receiving OPAT, which subsequently led to a readmission as neurological symptoms worsened. Cefepime was discontinued and symptoms resolved within 48 hours. Renal function was stable throughout treatment and no other causes for neurotoxicity were noted. Conclusion: This is a unique case of CIN secondary to shortened infusion time, which is clinically relevant, particularly during transitions of care. Further investigation, including more widespread use of therapeutic drug monitoring will be beneficial to further elucidate the relationship between infusion time and CIN development. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. High Prevalence of ESBL Genes in Commensal Escherichia coli of the Urinary Tract: Implications for Antibiotic Stewardship among Residents of Ghanaian Elderly Nursing Care Homes.
- Author
-
Armah, Emmanuel, Osae-Nyarko, Lawrencia, Idun, Bright, Ahiabu, Mawutor Kwame, Agyapong, Isaac, Kwarteng, Freda Boampong, Oppong, Mercy, Mohammed, Naael, Kotey, Fleischer C. N., Osei-Atweneboana, Mike Yaw, and Dayie, Nicholas T. K. D.
- Subjects
- *
ESCHERICHIA coli , *URINARY tract infections , *OLDER people , *MICROBIAL sensitivity tests , *ANTIMICROBIAL stewardship , *BETA lactamases , *CEFEPIME - Abstract
The emergence and spread of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (E. coli) pose significant challenges to the treatment and control of urinary tract infections, particularly among vulnerable populations, such as the elderly living in nursing care homes. In this study, we investigated the occurrence of ESBL genes in commensal E. coli isolated from urine samples of 118 elderly individuals residing in Ghanaian nursing care homes. A total of 195 ESBL genes were detected among 41 E. coli isolated from the study participants. All the isolates harboured at least one ESBL gene, and the majority of them (70.1%) carried at least four ESBL genes. Among the ESBL genes detected, CTXM825 was the predominant (14.1%). In antimicrobial susceptibility testing, 65.9% of the isolates showed resistance to cefepime, a fourth-generation cephalosporin, while 56.1% showed resistance to cefotaxime, a third-generation cephalosporin. Additionally, 46.3% of the isolates were multidrug-resistant, indicating resistance to antibiotics from multiple classes. In summary, we observed relatively high rates of resistance to antibiotics as well as alarming rates of ESBL genes in the isolated pathogens. These findings emphasise the urgent need for antimicrobial stewardship and infection control programmes to mitigate the spread of multidrug-resistant pathogens in nursing care homes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. Cefepime Neurotoxicity in Patients With Normal Renal Function: An Overlooked Cause of Encephalopathy in the Intensive Care Unit.
- Author
-
Alagha, Zakaria, Crow, Samuel, Abdeen, Abdul Muhsen Z., Alastal, Maha, and Alastal, Amro
- Abstract
Cefepime is a fourth-generation cephalosporin with extended antimicrobial coverage. Concerns have been raised about the side effects of cefepime including myoclonus, encephalopathy, and seizures, especially when renal impairment is present. There have been reports of cases of adverse neurological consequences despite appropriate renal adjustment. Here, we present a case of a 69-year-old patient initially diagnosed with pneumonia and treated with cefepime. The patient later developed altered mental status, leading to differential diagnoses including stroke, drug overdose, or non-convulsive seizures. Following a comprehensive workup, it was determined that she had cefepime-induced encephalopathy, despite having normal kidney function, which resolved completely after discontinuing the medication. In addition, we include similar cases retrieved from PubMed up to the present date, to the best of our knowledge. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. Mutation Rate of AmpC β-Lactamase–Producing Enterobacterales and Treatment in Clinical Practice: A Word of Caution.
- Author
-
Maillard, Alexis, Dortet, Laurent, Delory, Tristan, Lafaurie, Matthieu, Bleibtreu, Alexandre, and group, for the Treatment of AmpC producing Enterobacterales study
- Subjects
- *
BACTERIAL proteins , *CARBAPENEMS , *ENTEROBACTERIACEAE diseases , *RETROSPECTIVE studies , *CEFEPIME , *ENTEROBACTERIACEAE , *GENETIC mutation , *BETA lactamases , *TREATMENT failure - Abstract
In a retrospective multicenter study of 575 patients with bloodstream infections or pneumonia due to wild-type AmpC β-lactamase–producing Enterobacterales, species with low in vitro mutation rates for AmpC derepression were associated with fewer treatment failures due to AmpC overproduction (adjusted hazard ratio, 0.5 [95% CI,.2–.9]). However, compared to cefepime/carbapenems, using third-generation cephalosporins as definitive therapy remained associated with this adverse outcome (15% vs 1%). [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. Colistin-, cefepime-, and levofloxacin-resistant Salmonella enterica serovars isolated from Egyptian chicken carcasses.
- Author
-
El-Saeed, Bassant Ashraf, Elshebrawy, Hend Ali, Zakaria, Amira Ibrahim, Abdelkhalek, Adel, and Sallam, Khalid Ibrahim
- Subjects
COLISTIN ,CEFEPIME ,SALMONELLA enterica ,CHICKENS ,MICROBIAL sensitivity tests ,AGGLUTINATION tests ,POLYMERASE chain reaction - Abstract
Objectives: The emergence of multidrug-resistant (MDR) Salmonella strains, especially resistant ones toward critically important antimicrobial classes such as fluoroquinolones and third- and fourth-generation cephalosporins, is a growing public health concern. The current study, therefore, aimed to determine the prevalence, and existence of virulence genes (invA, stn, and spvC genes), antimicrobial resistance profiles, and the presence of β-lactamase resistance genes (bla
OXA , blaCTX-M1 , blaSHV , and blaTEM ) in Salmonella strains isolated from native chicken carcasses in Egypt marketed in Mansoura, Egypt, as well as spotlight the risk of isolated MDR, colistin-, cefepime-, and levofloxacin-resistant Salmonella enterica serovars to public health. Methods: One hundred fifty freshly dressed native chicken carcasses were collected from different poultry shops in Mansoura City, Egypt between July 2022 and November 2022. Salmonella isolation was performed using standard bacteriological techniques, including pre-enrichment in buffered peptone water (BPW), selective enrichment in Rappaport Vassiliadis broth (RVS), and cultivating on the surface of xylose-lysine-desoxycholate (XLD) agar. All suspected Salmonella colonies were subjected to biochemical tests, serological identification using slide agglutination test, and Polymerase Chain Reaction (PCR) targeting the invasion A gene (invA; Salmonella marker gene). Afterward, all molecularly verified isolates were screened for the presence of virulence genes (stn and spvC). The antimicrobial susceptibility testing for isolated Salmonella strains towards the 16 antimicrobial agents tested was analyzed by Kirby–Bauer disc diffusion method, except for colistin, in which the minimum inhibition concentration (MIC) was determined by broth microdilution technique. Furthermore, 82 cefotaxime-resistant Salmonella isolates were tested using multiplex PCR targeting the β-lactamase resistance genes, including blaOXA , blaCTX-M1 , blaSHV , and blaTEM genes. Results: Salmonella enterica species were molecularly confirmed via the invA Salmonella marker gene in 18% (27/150) of the freshly dressed native chicken carcasses. Twelve Salmonella serotypes were identified among 129 confirmed Salmonella isolates with the most predominant serotypes were S. Kentucky, S. Enteritidis, S. Typhimurium, and S. Molade with an incidence of 19.4% (25/129), 17.1% (22/129), 17.1% (22/129), and 10.9% (14/129), respectively. All the identified Salmonella isolates (n = 129) were positive for both invA and stn genes, while only 31.8% (41/129) of isolates were positive for the spvC gene. One hundred twenty-one (93.8%) of the 129 Salmonella-verified isolates were resistant to at least three antibiotics. Interestingly, 3.9%, 14.7%, and 75.2% of isolates were categorized into pan-drug-resistant, extensively drug-resistant, and multidrug-resistant, respectively. The average MAR index for the 129 isolates tested was 0.505. Exactly, 82.2%, 82.2%, 63.6%, 51.9%, 50.4%, 48.8%, 11.6%, and 10.1% of isolated Salmonella strains were resistant to cefepime, colistin, cefotaxime, ceftazidime/clavulanic acid, levofloxacin, ciprofloxacin, azithromycin, and meropenem, respectively. Thirty-one out (37.8%) of the 82 cefotaxime-resistant Salmonella isolates were β-lactamase producers with the blaTEM as the most predominant β-lactamase resistance gene, followed by blaCTX-M1 and blaOXA genes, which were detected in 21, 16, and 14 isolates respectively). Conclusion: The high prevalence of MDR-, colistin-, cefepime-, and levofloxacin-resistant Salmonella serovars among Salmonella isolates from native chicken is alarming as these antimicrobials are critically important in treating severe salmonellosis cases and boost the urgent need for controlling antibiotic usage in veterinary and human medicine to protect public health. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
17. The individual contributions of blaB, blaGOB and blaCME on MICs of β-lactams in Elizabethkingia anophelis.
- Author
-
Chen, Pei-Jing, Tan, Mei-Chen, Huang, Wei-Cheng, Hsu, Shu-Yuan, Chen, Te-Li, Yang, Chiou-Ying, and Kuo, Shu-Chen
- Subjects
- *
CEFTAZIDIME , *CEFEPIME , *GREATER wax moth , *LACTAMS , *DELETION mutation , *PIPERACILLIN , *CARBAPENEMS , *ESCHERICHIA coli - Abstract
Background The bla B, bla GOB and bla CME genes are thought to confer β-lactam resistance to Elizabethkingia anophelis , based on experiments conducted primarily on Escherichia coli. Objectives To determine the individual contributions of β-lactamase genes to increased MICs in E. anophelis and to assess their impact on the in vivo efficacy of carbapenem therapy. Methods Scarless gene deletion of one or more β-lactamase gene(s) was performed in three clinical E. anophelis isolates. MICs were determined by broth microdilution. Hydrolytic activity and expressions of β-lactamase genes were measured by an enzymatic assay and quantitative RT–PCR, respectively. In vivo efficacy was determined using Galleria mellonella and murine thigh infection models. Results The presence of bla B resulted in >16-fold increases, while bla GOB caused 4–16-fold increases of carbapenem MICs. Hydrolysis of carbapenems was highest in lysates of bla B-positive strains, possibly due to the constitutionally higher expression of bla B. Imipenem was ineffective against bla B-positive isolates in vivo in terms of improvement of the survival of wax moth larvae and reduction of murine bacterial load. The deletion of bla B restored the efficacy of imipenem. The bla B gene was also responsible for a >4-fold increase of ampicillin/sulbactam and piperacillin/tazobactam MICs. The presence of bla CME, but not bla B or bla GOB, increased the MICs of ceftazidime and cefepime by 8–16- and 4–8-fold, respectively. Conclusions The constitutionally and highly expressed bla B gene in E. anophelis was responsible for increased MICs of carbapenems and led to their poor in vivo efficacy. bla CME increased the MICs of ceftazidime and cefepime. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
18. APLICAÇÃO DA TERAPIA FOTODINÂMICA ANTIMICROBIANA SOBRE CEPA DE Staphylococcus aureus ISOLADA DE UMA LESÃO VENOSA.
- Author
-
Bastos, Daniela, Nogueira Soares, Kelly Cristina, Herrerias, Tatiana, and Toyomi Tominaga, Tania
- Subjects
OXACILLIN ,METHYLENE blue ,PHOTODYNAMIC therapy ,CEFEPIME ,STAPHYLOCOCCUS aureus ,IMIPENEM ,WOUND healing - Abstract
Copyright of Revista Foco (Interdisciplinary Studies Journal) is the property of Revista Foco and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2024
- Full Text
- View/download PDF
19. Combinations of Antibiotics Effective against Extensively- and Pandrug-Resistant Acinetobacter baumannii Patient Isolates.
- Author
-
Halim, Justin, Carr, Rachel A., Fliorent, Rebecca, Jonnalagadda, Keertana, Kurbonnazarova, Maftuna, Kaur, Muskanjot, Millstein, Ian, and Carabetta, Valerie J.
- Subjects
ACINETOBACTER baumannii ,DRUG resistance in bacteria ,CEFEPIME ,CRITICALLY ill ,MINOCYCLINE - Abstract
Infections due to drug-resistant Acinetobacter baumannii strains are increasing and cause significant morbidity and mortality, especially in hospitalized and critically ill patients. A. baumannii rapidly develops resistance to numerous antibiotics, and antibiotics traditionally used against this deadly pathogen have been failing in recent years, highlighting the need to identify new treatment strategies. Treatment options that have shown promise include revisiting common antibiotics not typically used against A. baumannii, evaluating new antibiotics recently introduced to market, and identifying combinations of antibiotics that display synergistic interactions. In this study, we characterized the antibiotic susceptibility profiles of extensively (XDR) and pandrug-resistant (PDR) A. baumannii patient isolates. We examined the potency of 22 standard-of-care antibiotics and the newer antibiotics eravacycline, omadacycline, and plazomicin against these strains. Furthermore, we examined combinations of these antibiotics against our collection to identify synergistic effects. We found that this collection is highly resistant to most or all standard-of-care antibiotics, except for minocycline and rifampin. We show that eravacycline and omadacycline are effective against these strains based on minimum inhibitory concentrations. We also identified two highly effective combinations, cefepime and amikacin and cefepime and ampicillin–sulbactam, which exhibited high rates of synergy against this collection. This information is valuable in our battle against highly drug resistant and virtually untreatable A. baumannii infections. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Isotope-dilution-LC-MS/MS candidate reference measurement procedure for cefepime in human serum
- Author
-
Judith Schäffler, Michael Vogeser, and Katharina Habler
- Subjects
Cefepime ,Isotope dilution-liquid chromatography-tandem mass spectrometry (ID-LC-MS/MS) ,Reference measurement procedures ,Metrological traceability ,Standardization ,Medical technology ,R855-855.5 - Abstract
Background: Reference measurement procedures are an essential element in the standardization and comparability of analytical measurement results in laboratory medicine. No LC-MS/MS-based reference measurement procedure for cefepime in serum has been published previously. Materials and methods: An isotope-dilution based two-dimensional LC-MS/MS reference measurement procedure for cefepime concentrations in human serum was developed and tested. The value assignment of unknown samples is based on a defined measurement series validation. Six unknown samples can be measured per series. Pass criteria for the run and the samples were determined empirically based on a performance evaluation. For this purpose, a between-run determination of five runs of the defined measurement series with six cefepime samples was carried out and evaluated. The goal was to define rigorous, realistic target limits and minimize measurement uncertainty. The final defined target limits are used for series-based validation and value assignment. The results for the six unknown samples are provided with the associated measurement uncertainty for this series. Results: The developed and extensively studied measurement procedure for the quantification of cefepime in serum was found to be practicable and fit for its purpose. The between-run mean imprecision of the six cefepime samples was ≤ 2.0 %, for the QCs it was ≤ 2.3 % and the between-run mean inaccuracy of the QCs was within ± 1.1 %. Conclusion: The novel isotope-dilution-LC-MS/MS measurement procedure in accordance to ISO 15193 can be recommended as candidate reference measurement procedure for the value assignment of cefepime concentrations in human serum.
- Published
- 2024
- Full Text
- View/download PDF
21. Mortality in Sepsis Patients Treated with Piperacillin-Tazobactam vs. Cefepime.
- Subjects
- *
ANTIBIOTICS , *PATIENTS , *HOSPITAL admission & discharge , *CEFEPIME , *HOSPITAL emergency services , *SEPSIS , *PENICILLIN - Abstract
The article focuses on comparing mortality rates in sepsis patients treated with piperacillin-tazobactam versus cefepime, finding that piperacillin-tazobactam was linked to higher mortality and longer organ dysfunction. Topics include the impact of anti-anaerobic antibiotics on the gut microbiome and immune system, the outcomes of patients treated with these antibiotics, and the implications for choosing empirical antibiotic therapy in sepsis without clear indications for anaerobic coverage.
- Published
- 2024
22. Cefepime and Enmetazobactam Injection (Exblifep).
- Subjects
- *
ANTIBIOTICS , *URINARY tract infections , *ENZYME inhibitors , *CEFEPIME , *PHARMACY information services , *INJECTIONS - Abstract
The article focuses on the FDA (U.S. Food and Drug Administration) approval of the combination drug cefepime and enmetazobactam (FPE) for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis. Key points discussed include the mechanism of action of FPE, its indication for use in patients 18 years and older, recommended dosage and advantages over existing treatments like piperacillin/tazobactam.
- Published
- 2024
23. Study of Cefepime-zidebactam (FEP-ZID) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
- Author
-
Medpace, Inc.
- Published
- 2023
24. Comparing Oral Versus Parenteral Antimicrobial Therapy (COPAT)
- Author
-
Joy J. Juskowich, MD, Assistant Professor
- Published
- 2023
25. BL Infusion Trial:Beta-lactam Continuous Versus Intermittent Infusion and Associated Bacterial Resistance and Therapy Outcomes in Critically Ill Patients With Severe Pneumonia
- Author
-
Food and Drug Administration (FDA)
- Published
- 2023
26. Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL) (OPTIMAL)
- Author
-
Vinay Badhwar, Executive Chair, Heart & Vascular Institute
- Published
- 2023
27. Early Antibiotics After Aspiration in ICU Patients
- Author
-
Mark Metersky, Chief, Division of Pulmonary, Critical Care and Sleep Medicine
- Published
- 2023
28. P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales (Integral-2)
- Published
- 2023
29. Antibiotic Plasma Concentrations During Continuous Renal Replacement Therapy With a High Adsorption Membrane (oXiris®)
- Author
-
Baxter Healthcare Corporation and Helena Colom Codina, Principal Investigator
- Published
- 2023
30. A targeted likelihood estimation comparing cefepime and piperacillin/tazobactam in critically ill patients with community-acquired pneumonia (CAP)
- Author
-
Cristian C. Serrano-Mayorga, Sara Duque, Elsa D. Ibáñez-Prada, Esteban Garcia-Gallo, María P. Rojas Arrieta, Alirio Bastidas, Alejandro Rodríguez, Ignacio Martin-Loeches, and Luis F. Reyes
- Subjects
Community-acquired pneumonia (CAP) ,Intensive care unit (ICU) ,Cefepime ,Piperacillin/tazobactam ,Targeted maximum likelihood estimation (TMLE) ,Medicine ,Science - Abstract
Abstract Cefepime and piperacillin/tazobactam are antimicrobials recommended by IDSA/ATS guidelines for the empirical management of patients admitted to the intensive care unit (ICU) with community-acquired pneumonia (CAP). Concerns have been raised about which should be used in clinical practice. This study aims to compare the effect of cefepime and piperacillin/tazobactam in critically ill CAP patients through a targeted maximum likelihood estimation (TMLE). A total of 2026 ICU-admitted patients with CAP were included. Among them, (47%) presented respiratory failure, and (27%) developed septic shock. A total of (68%) received cefepime and (32%) piperacillin/tazobactam-based treatment. After running the TMLE, we found that cefepime and piperacillin/tazobactam-based treatments have comparable 28-day, hospital, and ICU mortality. Additionally, age, PTT, serum potassium and temperature were associated with preferring cefepime over piperacillin/tazobactam (OR 1.14 95% CI [1.01–1.27], p = 0.03), (OR 1.14 95% CI [1.03–1.26], p = 0.009), (OR 1.1 95% CI [1.01–1.22], p = 0.039) and (OR 1.13 95% CI [1.03–1.24], p = 0.014)]. Our study found a similar mortality rate among ICU-admitted CAP patients treated with cefepime and piperacillin/tazobactam. Clinicians may consider factors such as availability and safety profiles when making treatment decisions.
- Published
- 2024
- Full Text
- View/download PDF
31. Intravenous push antibiotics in the emergency department: Education and implementation.
- Author
-
Brady, Rachel E, Giordullo, Elizabeth L, Harvey, Charles A, Krabacher, Nicholas D, and Penick, Alyssa M
- Subjects
- *
NURSING education , *ANTIBIOTICS , *SATISFACTION , *CEFAZOLIN , *HOSPITAL emergency services , *CEFEPIME , *DESCRIPTIVE statistics , *RETROSPECTIVE studies , *TREATMENT duration , *INTRAVENOUS therapy , *NURSES' attitudes , *MEDICAL records , *ACQUISITION of data , *SEPSIS , *TIME , *MEDICAL care costs , *EMERGENCY nurses , *CEFTRIAXONE , *MEROPENEM - Abstract
Purpose Intravenous push antibiotics can serve as an alternative to intravenous piggyback antibiotics while providing the same pharmacodynamics and adverse effect profile, easing shortage pressures and decreasing order to administration time, as well as representing a potential cost savings. The purpose of this study was to determine whether intravenous push antibiotics could decrease the time from an order to the start of administration compared to piggyback antibiotics in emergency departments. This study also measured the cost savings of antibiotic preparation and administration and assessed nursing satisfaction when using intravenous push antibiotics. Methods Sample instances of use of intravenous push and piggyback antibiotics were identified. Patients were included if they were 18 years of age or older and received at least a single dose of intravenous push or piggyback ceftriaxone, cefepime, cefazolin, or meropenem in one of the institution's emergency departments. The primary outcome of the study was to compare the time from the order to the start of administration of intravenous push vs piggyback antibiotics. The secondary outcome was to compare the cost of antibiotic preparation for the 2 methods. Results The intravenous push and piggyback groups each had 43 patients. The time from the order to the start of administration decreased from 74 (interquartile range, 29-114) minutes in the piggyback group to 31 (interquartile range, 21-52) minutes in the push group (P = 0.003). When the estimated monthly cost savings for ceftriaxone, cefepime, and meropenem were added together, across the emergency departments, an estimated $227,930.88 is saved per year when using intravenous push antibiotics. Conclusion Intravenous push antibiotics decrease the time from ordering to the start of administration and result in significant cost savings. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
32. Real-world utilization of ceftazidime/avibactam among inpatients in the national Veterans Affairs Healthcare System.
- Author
-
Caffrey, Aisling R, Appaneal, Haley J, Lopes, Vrishali V, Riccobene, Todd A, and LaPlante, Kerry L
- Subjects
- *
COMBINATION drug therapy , *URINARY tract infections , *PNEUMONIA , *RESEARCH funding , *DRUG resistance in microorganisms , *PEOPLE of color , *HYPERTENSION , *OSTEOMYELITIS , *BACTEREMIA , *HOSPITAL patients , *RETROSPECTIVE studies , *DESCRIPTIVE statistics , *CEFEPIME , *LONGITUDINAL method , *NEUROLOGICAL disorders , *VANCOMYCIN , *CEFTAZIDIME , *CEPHALOSPORINS , *CONFIDENCE intervals , *TUMORS , *LENGTH of stay in hospitals , *TREATMENT effect heterogeneity , *DATA analysis software , *VETERANS' hospitals , *REGRESSION analysis , *PSEUDOMONAS , *KLEBSIELLA , *DIABETES , *TIME , *MEROPENEM , *PENICILLIN ,MORTALITY risk factors - Abstract
Purpose Multidrug-resistant (MDR) infections are challenging to treat due to underlying patient conditions, pathogen characteristics, and high antibiotic resistance rates. As newer antibiotic therapies come to market, limited data exist about their real-world utilization. Methods This was a national retrospective cohort study of ceftazidime/avibactam (approved in 2015) utilization among inpatients from the Veterans Affairs (VA) Healthcare System, from 2015 through 2021. Joinpoint regression was used to estimate time trends in utilization. Results Ceftazidime/avibactam use increased by 52.3% each year (days of therapy per 1,000 bed days; 95% confidence interval, 12.4%-106.4%). We identified 1,048 unique predominantly male (98.3%) and white (66.2%; Black, 27.7%) patients treated with ceftazidime/avibactam, with a mean (SD) age of 71.5 (11.9) years. The most commonly isolated organisms were Pseudomonas aeruginosa (36.3%; carbapenem resistant, 80.6%; MDR, 65.0%) and Klebsiella species (34.1%; carbapenem resistant, 78.4%; extended-spectrum cephalosporin resistant, 90.7%). Common comorbid conditions included hypertension (74.8%), nervous system disorders (60.2%), diabetes mellitus (48.7%), and cancer (45.1%). Median time to ceftazidime/avibactam initiation from admission was 6 days, with a median of 3 changes in therapy before ceftazidime/avibactam initiation and a subsequent median length of inpatient stay of 14 days (median of 8 days of ceftazidime/avibactam therapy). Treatment heterogeneity was high, both before ceftazidime/avibactam initiation (89.6%) and during ceftazidime/avibactam treatment (85.6%), and common concomitant antibiotics included vancomycin (41.4%), meropenem (24.1%), cefepime (15.2%), and piperacillin/tazobactam (15.2%). The inpatient mortality rate was 23.6%, and 20.8% of patients had a subsequent admission with ceftazidime/avibactam treatment. Conclusion Utilization of ceftazidime/avibactam increased from 2015 to 2021 in the national VA Healthcare System. Ceftazidime/avibactam was utilized in complex, difficult-to-treat patients, with substantial treatment heterogeneity and variation in the causative organism and culture sites. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
33. A targeted likelihood estimation comparing cefepime and piperacillin/tazobactam in critically ill patients with community-acquired pneumonia (CAP).
- Author
-
Serrano-Mayorga, Cristian C., Duque, Sara, Ibáñez-Prada, Elsa D., Garcia-Gallo, Esteban, Arrieta, María P. Rojas, Bastidas, Alirio, Rodríguez, Alejandro, Martin-Loeches, Ignacio, and Reyes, Luis F.
- Subjects
- *
CEFEPIME , *COMMUNITY-acquired pneumonia , *PIPERACILLIN , *TAZOBACTAM , *CRITICALLY ill , *MAXIMUM likelihood statistics - Abstract
Cefepime and piperacillin/tazobactam are antimicrobials recommended by IDSA/ATS guidelines for the empirical management of patients admitted to the intensive care unit (ICU) with community-acquired pneumonia (CAP). Concerns have been raised about which should be used in clinical practice. This study aims to compare the effect of cefepime and piperacillin/tazobactam in critically ill CAP patients through a targeted maximum likelihood estimation (TMLE). A total of 2026 ICU-admitted patients with CAP were included. Among them, (47%) presented respiratory failure, and (27%) developed septic shock. A total of (68%) received cefepime and (32%) piperacillin/tazobactam-based treatment. After running the TMLE, we found that cefepime and piperacillin/tazobactam-based treatments have comparable 28-day, hospital, and ICU mortality. Additionally, age, PTT, serum potassium and temperature were associated with preferring cefepime over piperacillin/tazobactam (OR 1.14 95% CI [1.01–1.27], p = 0.03), (OR 1.14 95% CI [1.03–1.26], p = 0.009), (OR 1.1 95% CI [1.01–1.22], p = 0.039) and (OR 1.13 95% CI [1.03–1.24], p = 0.014)]. Our study found a similar mortality rate among ICU-admitted CAP patients treated with cefepime and piperacillin/tazobactam. Clinicians may consider factors such as availability and safety profiles when making treatment decisions. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
34. Cefepime/Enmetazobactam: First Approval.
- Author
-
Keam, Susan J.
- Subjects
- *
URINARY tract infections , *PNEUMONIA , *BACTEREMIA , *CEFEPIME , *VENTILATOR-associated pneumonia , *PYELONEPHRITIS , *NOSOCOMIAL infections , *MOLECULAR structure , *GRAM-negative bacteria - Abstract
Cefepime/enmetazobactam (EXBLIFEP®), an intravenous (IV) antibacterial fixed-dose combination of a 4th generation cephalosporin and an extended-spectrum β-lactamase (ESBL) inhibitor, is being developed by Allecra Therapeutics and ADVANZ PHARMA for the treatment of infections caused by multi-drug-resistant (MDR) Gram-negative bacteria. In February 2024, cefepime/enmetazobactam was approved in the USA for use in adults with complicated urinary tract infections (cUTI) including pyelonephritis, caused by susceptible strains of Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis, and Enterobacter cloacae complex. In March 2024, cefepime/enmetazobactam was approved in the EU for use in adults for the treatment of cUTI, including pyelonephritis, and hospital-acquired pneumonia, including ventilator associated pneumonia, and the treatment of patients with bacteraemia occurring in association with or suspected to be associated with any of these infections. This article summarizes the milestones in the development of cefepime/enmetazobactam leading to this first approval for the treatment of adults with infections caused by MDR Gram-negative bacteria. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
35. Cefepime-induced neurotoxicity in non-critically ill medical patients: a retrospective cohort study.
- Author
-
Almulhim, Abdulaziz S.
- Subjects
- *
NEUROTOXICOLOGY , *ALZHEIMER'S disease , *INTENSIVE care units , *CENTRAL nervous system , *COHORT analysis - Abstract
Studies had reported the association between cefepime and neurotoxicity. The neurotoxicity incidence was well documented regarding the intensive care unit (ICU). This study was aimed to evaluate the incidence and characteristics of neurotoxicity caused by cefepime in the medical patients. A retrospective study was conducted on the medical patients treated with cefepime. Patients having received cefepime were eligible for the screening. Exclusion criteria were as follows: admitted in ICU, Alzheimer’s disease, admitted with the altered mental status because of any cause or epilepsy history. Naranjo adverse event scale described the probability of adverse events in suspected cases and categorized as definite, probable, possible and doubtful. A total of 601 patients were screened wherein 93 met the inclusion criteria. The mean age (±standard deviation (SD)) was 56 years (±17). The patients’ majority was male (66%) with the normal kidney function (73%). Common comorbidities included hypertension (60%) and diabetes (40%). Only 2 patients (2%) had developed neurological symptoms. The cases were carefully evaluated where one was doubtful and the other possibly had cefepime-induced neurotoxicity. The neurotoxicity incidence among medical patients was low, and might relate to the disease states affecting central nervous system. Hence, a careful evaluation of other possible causes for neurological symptoms deemed necessary while being on cefepime therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
36. A New "Non-Traditional" Antibacterial Drug Fluorothiazinone—Clinical Research in Patients with Complicated Urinary Tract Infections.
- Author
-
Zigangirova, Nailya A., Lubenec, Nadezda L., Beloborodov, Vladimir B., Sheremet, Anna B., Nelyubina, Stanislava A., Bondareva, Nataliia E., Zakharov, Konstantin A., Luyksaar, Sergey I., Zolotov, Sergey A., Levchenko, Evgenia U., Luyksaar, Svetlana V., Koroleva, Ekaterina A., Fedina, Elena D., Simakova, Yana V., Pushkar, Dmitry Yu., and Gintzburg, Alexander L.
- Subjects
CEFEPIME ,URINARY tract infections ,MEDICAL research ,ANTI-infective agents ,DISEASE relapse ,SMALL molecules - Abstract
In order to combat resistance, it is necessary to develop antimicrobial agents that act differently from conventional antibiotics. Fluorothiazinone, 300 mg tablet (The Gamaleya National Research Center), is an original antibacterial drug based on a new small molecule T3SS and flagellum inhibitor. A total of 357 patients with complicated urinary tract infections (UTIs) were divided into two groups and given Fluorothiazinone 1200 mg/day or a placebo for 7 days to evaluate the efficacy and safety of the drug. Additionally, all patients were given Cefepime 2000 mg/day. Fluorothiazinone with Cefepime showed superiority over placebo/Cefepime based on the assessment of the proportion of patients with an overall outcome in the form of a cure after 21 days post-therapy (primary outcome), overall outcome in cure rates, clinical cure rates, and microbiological efficacy at the end of therapy and after 21 days post-therapy (secondary outcomes). In patients who received Fluorothiazinone, the rate of infection recurrences 53 and 83 days after the end of the therapy was lower by 18.9%, compared with patients who received placebo. Fluorothiazinone demonstrated a favorable safety profile with no serious unexpected adverse events reported. The results showed superiority of the therapy with Fluorothiazinone in combination with Cefepime compared with placebo/Cefepime in patients with cUTIs. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
37. Statistical design and optimization of nano-transfersomes based chitosan gel for transdermal delivery of cefepime.
- Author
-
Mirza, Rashna, Shah, Kifayat Ullah, Khan, Atif Ullah, Fawad, Mohsin, Rehman, Asim Ur, Ahmed, Naveed, Nawaz, Asif, Shah, Shefaat Ullah, Alasmari, Abdullah F., Alharbi, Metab, Alasmari, Fawaz, Hafeez, Zeeshan, and Haq, Sami Ul
- Subjects
CEFEPIME ,EXPERIMENTAL design ,CHITOSAN ,SONICATION ,PATIENT compliance ,ZETA potential ,ANTIBACTERIAL agents - Abstract
This research aimed to overcome challenges posed by cefepime excessive elimination rate and poor patient compliance by developing transdermal delivery system using nano-transfersomes based chitosan gel. Rotary evaporation-sonication method and the Box-Behnken model were used to prepare cefepime loaded nano-transfersomes (CPE-NTFs). The physiochemical characterization of CPE-NTFs were analyzed including DLS, deformability index, DSC and antimicrobial study. Optimized CPE-NTFs loaded into chitosan gel and appropriately characterized. In vitro release, ex vivo and in vivo studies were performed. The CPE-NTFs were physically stable with particle size 222.6 ± 1.8 nm, polydispersity index 0.163 ± 0.02, zeta potential −20.8 ± 0.1 mv, entrapment efficiency 81.4 ± 1.1% and deformability index 71 ± 0.2. DSC analysis confirmed successful drug loading and thermal stability. FTIR analysis showed no chemical interaction among the excipients of CPE-NTFs gel. The antibacterial activity demonstrated a remarkable reduction in the minimum inhibitory concentration of cefepime when incorporated into nano-transfersomes. CPE-NTFs based chitosan gel (CPE-NTFs gel) showed significant physicochemical properties. In vitro release studies exhibited sustained release behavior over 24 h, and ex vivo studies indicated enhanced permeation and retention compared to conventional cefepime gel. In vivo skin irritation studies confirmed CPE-NTFs gel was nonirritating and biocompatible for transdermal delivery. This research showed nano-transfersomes based chitosan gel is a promising approach for cefepime transdermal delivery and provides sustained release of cefepime. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
38. Treatment Outcomes for Carbapenem-Resistant and Cephalosporin-Susceptible Pseudomonas aeruginosa Pneumonia.
- Author
-
Ng, Tsz Hin, Zhao, Jing J., Gumbleton, Ryan, Olson, Shannon, Smith, Stephanie, and Scipione, Marco R.
- Subjects
CARBAPENEM-resistant bacteria ,PSEUDOMONAS aeruginosa ,TREATMENT effectiveness ,VENTILATOR-associated pneumonia ,HOSPITAL mortality ,POLYHYDRAMNIOS ,KLEBSIELLA infections - Abstract
Background: Carbapenem-resistant (Car-R) Pseudomonas aeruginosa is an urgent threat. These isolates may remain susceptible to traditional noncarbapenem antipseudomonal β-lactams, but it is unclear if carbapenem resistance impacts the effectiveness of these agents. Objective: The purpose of this study was to compare clinical outcomes in Car-R and cephalosporin-susceptible (Ceph-S) P. aeruginosa pneumonia treated with cefepime versus other susceptible agents. Methods: This retrospective cohort study evaluated patients diagnosed with hospital-acquired or ventilator-associated pneumonia who had a respiratory isolate of Car-R Ceph-S P. aeruginosa. Patients were excluded if they had polymicrobial respiratory cultures, other concomitant infections, empyema, death within 3 days of index culture, or received less than 3 days of susceptible therapy. Patients treated with cefepime were compared to other susceptible therapies. The primary endpoint was 30-day in-hospital mortality. Results: Eighty-seven patients were included: cefepime, n = 61; other susceptible therapies, n = 26. There were no differences in 30-day in-hospital mortality between cefepime and other susceptible therapies (19.6% vs. 19.2%, p value = 0.719). In addition, there were no differences between clinical cure rates (cefepime 65.6% vs. other therapies 72 %, p value = 0.47). In multivariate logistic regression, treatment with cefepime (odds ratio [OR], 0.57; 95% confidence interval [CI], 0.11-2.52) was not independently associated with 30-day in-hospital mortality. Conclusion and Relevance: For the treatment of Car-R Ceph-S P. aeruginosa pneumonia, cefepime showed similar rates of 30-day in-hospital mortality and clinical outcomes when compared to other susceptible therapies. Cefepime may be utilized to conserve novel β-lactam and β-lactamase inhibitors. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
39. Antimicrobial Resistance and Associated Risk Factors for Clostridium difficile in Patients Attending Tertiary Care Settings.
- Author
-
Mubaraki, Murad A., Hussain, Mubbashir, Hassan, Faaiz Ul, Munir, Shahzad, Fozia, Fozia, Ahmad, Ijaz, Bibi, Fatima, Sultan, Samia, and Zialluh, Ziaullah
- Subjects
- *
CLOSTRIDIOIDES difficile , *CLOSTRIDIUM , *DRUG resistance in microorganisms , *TERTIARY care , *ENZYME-linked immunosorbent assay , *CEFEPIME , *ENTEROCOCCAL infections , *SHIGELLOSIS - Abstract
To determine the incidence of antimicrobial-resistant emerging pathogens, Clostridium difficile, and its associated risk factors in tertiary care setups of Pakistan. This cross-sectional prospective study was conducted from January 2019 to December 2020, to determine the prevalence and antimicrobial resistance patterns of C. difficile strains isolated from 450 stool specimens of patients suffering from diarrhea hospitalized in tertiary care hospitals in Peshawar, Pakistan. The stool samples of the patients were processed for culture and detection of toxin A and toxin B by enzyme-linked immunosorbent assay (ELISA) and tpi PCR. The drug sensitivity test was performed for antibiotics including ampicillin, cefixime, cefepime, amoxicillin, nalidixic acid, sulpha/TMP (SXT), chloramphenicol, metronidazole, vancomycin, ciprofloxacin, levofloxacin, and imipenem. Of 450 stool specimens, 108 (24%) were positive for C. difficile by stool culture, whereas 115 (25.5%) were only positive for C. difficile toxins based on ELISA and PCR (128 (28.6%). Of 108, 90.7% (n = 98) isolates were resistant to one antibiotic, and 90 (83.4%) were resistant to three or more antimicrobials. The highest resistance rates were found against penicillin (83.3%) followed by amoxicillin (70%), nalidixic acid (61%), and metronidazole (38%), and the lowest resistance was found against vancomycin (6.4%) and imipenem (3.7%). CDI was statistically significantly correlated with increased age, use of antibiotics, abdominal surgeries, use of proton pump inhibitors and H2a, and presence of comorbidities. The high frequency of C. difficile in Peshawar, Pakistan, indicates that CDI is an important nosocomial infection in different hospitals. The results will be helpful for clinicians to redesign control and therapeutic strategies in hospitals. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
40. Seraph 100 Microbind Affinity Blood Filter Does Not Clear Antibiotics: An Analysis of Antibiotic Concentration Data from PURIFY-OBS.
- Author
-
DeLuca, Jesse P., Selig, Daniel J., Vir, Pooja, Vuong, Chau V., Della-Volpe, Jeffrey, Rivera, Ian M., Park, Caroline, Levi, Benjamin, Pratt, Kathleen P., and Stewart, Ian J.
- Subjects
- *
ANTIBIOTICS , *BETA-lactamase inhibitors , *CEFEPIME , *CEFAZOLIN , *ANTI-infective agents , *HEMOPERFUSION - Abstract
Introduction: Novel hemoperfusion systems are emerging for the treatment of sepsis. These devices can directly remove pathogens, pathogen-associated molecular patterns, cytokines, and other inflammatory markers from circulation. However, significant safety concerns such as potential antibiotic clearance need to be addressed prior to these devices being used in large clinical studies. Methods: Prospective, observational study of 34 participants undergoing treatment with the Seraph 100® Microbind Affinity Blood Filter (Seraph 100) device at 6 participating sites in the USA. Patients were included for analysis if they had a record of receiving an antibiotic concurrent with Seraph 100 treatment. Patients were excluded if there was missing information for blood flow rate. Blood samples were drawn pre- and post-filter at 1 h and 4 h after treatment initiation. These average pre- and post-filter time-concentration observations were then used to estimate antibiotic clearance in L/h (CLSeraph) due to the Seraph 100 device. Results: Of the 34 participants in the study, 17 met inclusion and exclusion criteria for the antibiotic analysis. Data were obtained for 7 antibiotics (azithromycin, cefazolin, cefepime, ceftriaxone, linezolid, piperacillin, and vancomycin) and one beta-lactamase inhibitor. Mean CLSeraph for the antibiotics investigated ranged from −0.57 to 0.47 L/h. No antibiotic had a CLSeraph statistically significant from 0. Discussion/Conclusion: The Seraph 100 did not significantly clear any measured antibiotic in clinical samples. These data give further evidence to suggest that these therapies may be safely administered to critically ill patients and will not impact concentrations of administered antibiotics. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
41. Towards optimizing cefepime/tazobactam (WCK 4282) exposure to achieve efficacy against piperacillin/tazobactam-resistant ESBL infections: dose recommendations for various renal functions, including intermittent haemodialysis, in healthy individuals.
- Author
-
Muller, Anouk E, Winter, Brenda C M De, and Koch, Birgit C P
- Subjects
- *
CEFEPIME , *TAZOBACTAM , *KIDNEY physiology , *HEMODIALYSIS , *PIPERACILLIN , *HEMODIALYSIS patients , *ANGIOTENSIN II - Abstract
Objectives WCK 4282 is a novel combination of cefepime 2 g and tazobactam 2 g being developed for the treatment of infections caused by piperacillin/tazobactam-resistant ESBL infections. The dosing regimen for cefepime/tazobactam needs to be optimized to generate adequate exposures to treat infections caused by ESBL-producing pathogens resistant to both cefepime and piperacillin/tazobactam. Methods We developed pharmacokinetic population models of cefepime and tazobactam to evaluate the optimal dose adjustments in patients, including those with augmented renal clearance as well as various degrees of renal impairment, and also for those on intermittent haemodialysis. Optimal doses for various degrees of renal function were identified by determining the PTA for a range of MICs. To cover ESBL-producing pathogens with an cefepime/tazobactam MIC of 16 mg/L, a dosing regimen of 2 g q8h infused over 1.5 h resulted in a combined PTA of 99% for the mean murine 1 log10-kill target for the cefepime/tazobactam combination. Results We found that to adjust for renal function, doses need to be reduced to 1 g q8h, 500 mg q8h and 500 mg q12h for patients with CLCR of 30–59, 15–29 and 8–14 mL/min (as well as patients with intermittent haemodialysis), respectively. In patients with high to augmented CLR (estimated CLCR 120–180 mL/min), a prolonged 4 h infusion of standard dose is required. Conclusions The suggested dosing regimens will result in exposures of cefepime and tazobactam that would be adequate for infections caused by ESBL-producing pathogens with a cefepime/tazobactam MICs up to 16 mg/L. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
42. Simultaneous detection of phylogroups and ESBL genes in E. coli using Multiplex PCR.
- Author
-
Patoli, Bushra B., Patoli, Atif A., Begum, Iram Nabi, and Majeed, Zarafshan
- Subjects
- *
ESCHERICHIA coli , *BETA lactamases , *DRUG resistance in bacteria , *GENE expression , *CEFOTAXIME , *CEFEPIME - Abstract
Background: Escherichia coli (E. coli) strains harbor various allelic versions of beta lactamase genes and their identification using conventional phenotypic tests is a tedious and time consuming task. In the present study, multiplex PCR is performed for the simulatanoues detection of E. coli phylogroups and extended-spectrum β-lactamase-(ESBL) genes. Methods: A total of 128 E. coli isolates from urine samples were screened for antibiotic resistance and expression of ESBL activity using phenotypic and genotypic methods. Uniplex and multiplex PCRs were used to detect E. coli phylogroup detrminants and blaCTX-M-15, blaOXA-1 and TEM1 genes. Chi Square test of independence was employed for evaluating significant levels at P value < 0.05. Results: Phylogroup B2 was detected as the predominant group (36%) followed by group D (30%), A (25%) and B1 (9%). The highest resistance was seen against nalidixic acid (100%) and the lowest against amoxicillinclavulanic acid (55%). Significant P values were observed for resistance against cefotaxime and cefepime in the phylogroup B2 while resistance against cefoxitin, sulfamethoxazole and fosfomycin was significantly associated with group D. Combination disc diffusion test (CDDT) showed ESBL activity in 42% E. coli isolates. A significant association of blaCTX-M-15 gene was observed for phylogroup B2 (P = 0.007). Moreover, a combination genotype of blaCTX-M-15 and TEM1 was also found statistically prevalent in phylogroup B2 (P = 0.006). Conclusion: The study highlights the alarming rise in antibiotic resistance and delineates B2 a predominant phylogoup with a high prevalence of blaCTX-M-15 and TEM1 genes in urinary E. coli isolates. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
43. Effectiveness of cephalosporins in hydrolysis and inhibition of Staphylococcus aureus and Escherichia coli biofilms.
- Author
-
Aslam, Jawaria, Ali, Hafiz Muhammad, Hussain, Shujaat, Ahmad, Muhammad Zishan, Siddique, Abu Baker, Shahid, Muhammad, Shahzad, Mirza Imran, Fatima, Hina, Tariq, Sarah, Sadiq, Fatima, Aslam, Maria, Farooq, Umar, Zia, Saadiya, Aljaluod, Rawa Saad, and Alarjani, Khaloud Mohammed
- Subjects
CEFEPIME ,ESCHERICHIA coli ,BIOFILMS ,CEPHALOSPORINS ,PHASE-contrast microscopy ,HYDROLYSIS ,GENTIAN violet - Abstract
Importance: Staphylococcus aureus and Escherichia coli contribute to global health challenges by forming biofilms, a key virulence element implicated in the pathogenesis of several infections. Objective: The study examined the efficacy of various generations of cephalosporins against biofilms developed by pathogenic S. aureus and E. coli. Methods: The development of biofilms by both bacteria was assessed using petri-plate and microplate methods. Biofilm hydrolysis and inhibition were tested using first to fourth generations of cephalosporins, and the effects were analyzed by crystal violet staining and phase contrast microscopy. Results: Both bacterial strains exhibited well-developed biofilms in petri-plate and microplate assays. Cefradine (first generation) showed 76.78% hydrolysis of S. aureus biofilm, while significant hydrolysis (59.86%) of E. coli biofilm was observed by cefipime (fourth generation). Similarly, cefuroxime, cefadroxil, cefepime, and cefradine caused 78.8%, 71.63%, 70.63%, and 70.51% inhibition of the S. aureus biofilms, respectively. In the case of E. coli, maximum biofilm inhibition (66.47%) was again shown by cefepime. All generations of cephalosporins were more effective against S. aureus than E. coli, which was confirmed by phase contrast microscopy. Conclusions and Relevance: Cephalosporins exhibit dual capabilities of hydrolyzing and inhibiting S. aureus and E. coli biofilms. First-generation cephalosporins exhibited the highest inhibitory activity against S. aureus, while the third and fourth generations significantly inhibited E. coli biofilms. This study highlights the importance of tailored antibiotic strategies based on the biofilm characteristics of specific bacterial strains. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
44. Cefepime distribution by microdialysis in peritoneal fluid of rats with or without experimental peritonitis.
- Author
-
Anjos, Michele Vaz, Possa, Eduarda, Fonseca, Gisele da Silva, Bergoza, Larissa, and Tasso, Leandro
- Abstract
The aim of this study was to investigate the penetration of cefepime into rat peritoneal fluid by microdialysis and to determine the relationship between unbound drug plasma and tissue concentration in healthy animals and in a sepsis model established through cecal ligation and puncture‐induced peritonitis. Probe recovery was performed by dialysis and retrodialysis. Cefepime was administered at a dose of 110 mg/kg intravenously. Samples were collected for about 4 h, and concentrations were determined by liquid chromatography‐electrospray ionization‐QTOF MS. Tissue penetration was also determined. Probe recovery in vivo was 38.78% ± 3.31% and 38.83% ± 2.74% in the control and peritonitis groups, respectively. Cefepime was rapidly distributed in the peritoneal fluid in both groups. The peritoneal fluid/plasma cefepime ratio was 0.38 and 0.32 for the control and peritonitis groups, respectively. Cefepime concentrations were above the MIC of 4 mg/L for the main enterobacteria. The infection model that was used had no apparent effect on the pharmacokinetics of cefepime in rats. This was the first study to determine free cefepime concentrations in the peritoneal fluid of healthy rats and rats with experimental peritonitis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
45. Fellows Column: Case Report: Neonatal Intraventricular Hemorrhage in E.coli K1 Meningitis.
- Author
-
Banh, Marian, Chawla, Rohan, Kohandani, Sara, and Patel, Monalisa
- Subjects
- *
DIAGNOSIS of escherichia coli diseases , *BACTERIAL meningitis , *BLOOD , *LEUKOCYTE count , *INTRAVENOUS immunoglobulins , *PLATELET count , *ERYTHROCYTES , *MICROBIAL sensitivity tests , *BACTERIAL antigens , *RARE diseases , *NEONATAL intensive care units , *NEUTROPHILS , *HEMOGLOBINS , *ELECTROENCEPHALOGRAPHY , *NEONATAL diseases , *CEFEPIME , *AMPICILLIN , *NEONATAL intensive care , *BLOOD platelet transfusion , *MAGNETIC resonance imaging , *CELL culture , *THROMBOCYTOPENIA , *BLOOD sugar , *GENTAMICIN , *APGAR score , *HEMATOCRIT , *RESPIRATORY distress syndrome , *CEREBRAL hemorrhage , *C-reactive protein , *CEREBROSPINAL fluid , *DISEASE complications - Abstract
The article offers information on neonatal meningitis, a rare but serious disease affecting newborns, with acute inflammation of the brain tissue. Topics include the categorization of neonatal meningitis into early and late onset, common pathogens like Group B Streptococcus and Escherichia coli, and risk factors such as prematurity and maternal colonization.
- Published
- 2024
46. Piperacillin/tazobactam versus cefepime or carbapenems for cefoxitin-non-susceptible Enterobacter cloacae, Klebsiella aerogenes, Citrobacter freundii, Serratia marcescens and Morganella morganii bacteraemia in immunocompromised patients
- Author
-
Lu, Brian, Wong, Miranda, Ha, David, Bounthavong, Mark, Banaei, Niaz, Deresinski, Stanley, and Diep, Calvin
- Subjects
Medical Microbiology ,Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Humans ,Cefepime ,Anti-Bacterial Agents ,Carbapenems ,Cefoxitin ,Enterobacter aerogenes ,Citrobacter freundii ,Serratia marcescens ,Morganella morganii ,Enterobacter cloacae ,Retrospective Studies ,Piperacillin ,Tazobactam Drug Combination ,Bacteremia ,beta-Lactamases ,Microbial Sensitivity Tests ,Microbiology ,Pharmacology and Pharmaceutical Sciences ,Clinical sciences ,Pharmacology and pharmaceutical sciences - Abstract
BackgroundThe role of piperacillin/tazobactam for treatment of serious infections due to AmpC-producing organisms remains debatable, particularly in immunocompromised patients.MethodsThis was a retrospective cohort study in immunocompromised patients that investigated the effect of definitive treatment with either piperacillin/tazobactam versus cefepime or carbapenems for bacteraemia caused by cefoxitin-non-susceptible Enterobacterales. The primary endpoint was a composite of clinical and microbiological failure. A logistic regression model was constructed to assess the impact of definitive treatment choice on the primary endpoint.ResultsA total of 81 immunocompromised patients with blood cultures positive for cefoxitin-non-susceptible Enterobacterales were included for analysis. There was more microbiological failure in the piperacillin/tazobactam arm compared with the cefepime/carbapenem arm (11.4% versus 0.0%, P = 0.019). Definitive treatment with cefepime or a carbapenem was associated with a decreased odds of clinical or microbiological failure (OR 0.303, 95% CI 0.093-0.991, P = 0.048) when controlling for baseline characteristics.ConclusionsIn immunocompromised patients with bacteraemia due to cefoxitin-non-susceptible Enterobacterales, definitive treatment with piperacillin/tazobactam was associated with an increased risk of microbiological failure and higher odds of clinical or microbiological failure compared with cefepime or carbapenems.
- Published
- 2023
47. Cefepime/sulbactam combination as a treatment alternative for extended spectrum beta-lacatmase producing Enterobacterales: A multicentric study from India
- Author
-
Yamuna Devi Bakthavatchalam, Dhanalakshmi Solaimalai, Anand Ashok, Harthi Ragothaman, Soniya Krishnamoorthy, Nivedhana Subburaju, Sanjay bhattacharya, Rudresh Sm, Shripad Murlidhar Taklikar, Barney Isaac, Kamini Walia, and Balaji Veeraraghavan
- Subjects
Cefepime ,Sulbactam ,ESBL ,OXA-1 ,Piperacillin/tazobactam ,Cefoperazone/sulbactam ,Public aspects of medicine ,RA1-1270 - Abstract
Background: Piperacillin/tazobactam has limited activity against Enterobacterales, which concurrently express ESBL/ampC/OXA-1 beta-lactamases, which are widely prevalent in India. Thus, there is a severe dearth for carbapenem sparing options that aggravate more dependent carbapenem therapy. In the Indian market, various cefepime/BLI combinations in diiferent fixed ratios were introduced to clinical practice. We investigated the activity of cefepime with increased sulbactam ratios against contemporary isolates of ESBL/OXA-1 expressing Enterobacterales. Methods: Non-duplicate contemporary ESBL and/or OXA-1 expressing E. coli (n = 117) and K. pneumoniae (n = 71) isolates were included in this study. The MIC of cefepime/sulbactam and its comparators were determined using a broth microdilution method. The presence of ESBL and OXA-1 genes were identified using multiplex PCR. Results: Against ESBL and OXA-1 co-producing E. coli, cefepime combined with sulbactam at 8 mg/L, inhibited 82% of the isolates. Cefoperazone susceptibility against ESBL-E. coli increased from 52% at 4 mg/L to 77% at 8 mg/L with sulbactam. When tested against K. pneumoniae co-expressing ESBL and OXA-1, cefepime susceptibility was 77% at 4 mg/L sulbactam and 88% at 8 mg/L sulbactam. PTZ consistently showed limited activity against ESBL co-harbouring OXA-1 (E. coli, 43% and K. pneumoniae, 61%). Conclusion: The present study demonstrates that adding an increased sulbactam concentration enhances cefepime's activity against contemporary ESBL/OXA-1 expressing Enterobacterales. A reformulated cefepime/sulbactam (2 g/2 g) combination may be the best carbapenem sparing option until cefepime/tazobactam and cefepime/enmetazobactam become available in the future.
- Published
- 2024
- Full Text
- View/download PDF
48. Trend of Antimicrobial Resistance of Gram-Negative Uropathogens Post Kidney Transplantation.
- Author
-
Sulaiman, Shabna, Nair, Priyanka R., Bhatt, Arun N., Hafeeq, Benil, Uvais, Nalakath A., Anoop, K. P. Miswana, and Aziz, Feroz
- Subjects
- *
MORTALITY prevention , *KIDNEY transplantation , *URINARY tract infections , *PUBLIC health surveillance , *THIRD generation cephalosporins , *CIPROFLOXACIN , *NITROFURANTOIN , *ANTIBIOTICS , *RISK assessment , *GRAFT survival , *DEATH , *PATIENTS , *TRANSPLANTATION of organs, tissues, etc. , *ENTEROBACTERIACEAE diseases , *DRUG resistance in microorganisms , *TREATMENT effectiveness , *DISEASE prevalence , *CEFEPIME , *LONGITUDINAL method , *KLEBSIELLA infections , *PSEUDOMONAS diseases , *ESCHERICHIA coli diseases , *URINALYSIS , *POSTOPERATIVE period , *GRAM-negative bacterial diseases , *CONFIDENCE intervals , *MEDICAL care costs , *LONGEVITY , *SULFAMETHOXAZOLE , *ACIDS , *PENICILLIN , *MEROPENEM , *DISEASE risk factors - Published
- 2024
- Full Text
- View/download PDF
49. Cefepime and Unictam on Preventing Post-Cesarean Surgical Site Infections
- Author
-
Sara Abdallah Mohamed Salem, principle investigator/Lecturer of Gynecology and obstetrics Faculty of medicine Beni-Suef University
- Published
- 2023
50. Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care (PTN_POPS)
- Author
-
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), The Emmes Company, LLC, and Daniel Benjamin, Professor of Pediatrics
- Published
- 2023
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.